Cellectis to Report Third Quarter Financial Results on November 7, 2025
Rhea-AI Summary
Cellectis (NASDAQ: CLLS) announced it will report its third quarter 2025 financial results for the period ended September 30, 2025 on Friday, November 7, 2025 after the U.S. market close.
The company said the press release will be posted in the Investors section of its website and that no conference call will be held to discuss results; investor inquiries may be directed to investors@cellectis.com.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CLLS declined 5.22%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2025 ending September 30, 2025 on Friday, November 7, 2025 after the close of the US market.
The press release will be available in the Investors section of Cellectis’ website: https://www.cellectis.com/en/investors/press-releases/
Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at investors@cellectis.com
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
FAQ
When will Cellectis (CLLS) release Q3 2025 financial results?
Where can I find the Cellectis (CLLS) Q3 2025 press release?
Will Cellectis (CLLS) host a conference call for the November 7, 2025 results?
How can investors contact Cellectis (CLLS) with questions about Q3 2025 results?
What reporting period does Cellectis' November 7, 2025 release cover?
